DS
COGT icon

David Shaw’s Cogent Biosciences COGT Stock Holding History

David Shaw’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.7M Sell
922,479
-945,910
-51% -$33.1M 0.02% 950
2026
Q1 		$71.9M Sell
1,868,389
-379,415
-17% -$14M 0.04% 508
2025
Q4 		$79.8M Buy
2,247,804
+716,879
+47% +$20.2M 0.04% 497
2025
Q3 		$22M Buy
1,530,925
+1,257,390
+460% +$14.9M 0.01% 1116
2025
Q2 		$1.96M Buy
273,535
+56,004
+26% +$310K ﹤0.01% 2750
2025
Q1 		$1.3M Sell
217,531
-122,457
-36% -$960K ﹤0.01% 2914
2024
Q4 		$2.65M Sell
339,988
-117,240
-26% -$1.17M ﹤0.01% 2508
2024
Q3 		$4.94M Buy
457,228
+158,517
+53% +$1.54M ﹤0.01% 1964
2024
Q2 		$2.52M Sell
298,711
-152,521
-34% -$1.16M ﹤0.01% 2450
2024
Q1 		$3.03M Buy
451,232
+392,431
+667% +$2.43M ﹤0.01% 2292
2023
Q4 		$346K Sell
58,801
-51,725
-47% -$396K ﹤0.01% 3685
2023
Q3 		$1.08M Sell
110,526
-91,630
-45% -$1.09M ﹤0.01% 3012
2023
Q2 		$2.39M Sell
202,156
-259,678
-56% -$2.98M ﹤0.01% 2483
2023
Q1 		$4.98M Sell
461,834
-271,626
-37% -$3.47M 0.01% 1940
2022
Q4 		$8.48M Sell
733,460
-166,613
-19% -$2.06M 0.01% 1586
2022
Q3 		$13.4M Buy
900,073
+704,172
+359% +$9.65M 0.02% 1123
2022
Q2 		$1.77M Buy
+195,901
New +$1.34M ﹤0.01% 3175
2022
Q1 		– Sell
-25,813
Closed -$221K – 5586
2021
Q4 		$221K Buy
+25,813
New +$224K ﹤0.01% 4828
2019
Q1 		– Sell
-13,739
Closed -$242K – 3633
2018
Q4 		$242K Buy
13,739
+961
+8% +$28.4K ﹤0.01% 3461
2018
Q3 		$526K Buy
+12,778
New +$720K ﹤0.01% 3085

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

David Shaw's COGT Position: Q2 2026 in Review

David Shaw reduced its Cogent Biosciences (COGT) stake by 51% in Q2 2026, selling an estimated $33.1M and leaving 922,479 shares worth $35.7M. The position accounts for 0.02% of the portfolio, ranked #950.

David Shaw first reported a position in COGT in Q3 2018 and has held it in 20 quarters since. The position peaked at $79.8M in Q4 2025. 322 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • David Shaw held 922,479 shares of Cogent Biosciences worth $35.7M as of Q2 2026.
  • David Shaw sold 945,910 Cogent Biosciences shares in Q2 2026, an estimated $33.1M.
  • Cogent Biosciences made up 0.02% of David Shaw's portfolio in Q2 2026, its #950 holding.
  • David Shaw first reported a position in Cogent Biosciences in Q3 2018 and has held it in 20 quarters since.
  • David Shaw's Cogent Biosciences position peaked at $79.8M in Q4 2025.
  • 322 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.